Twist Bioscience Co. (NASDAQ:TWST) CEO Emily M. Leproust Sells 1,732 Shares

Twist Bioscience Co. (NASDAQ:TWST) CEO Emily M. Leproust sold 1,732 shares of the firm’s stock in a transaction dated Thursday, June 20th. The stock was sold at an average price of $49.41, for a total value of $85,578.12. Following the sale, the chief executive officer now directly owns 505,846 shares in the company, valued at approximately $24,993,850.86. The sale was disclosed in a document filed with the SEC, which is accessible through this link.

Twist Bioscience Trading Down 3.4 %

Shares of TWST stock opened at $49.26 on Tuesday. The business’s 50 day moving average is $42.29 and its two-hundred day moving average is $37.85. Twist Bioscience Co. has a twelve month low of $14.42 and a twelve month high of $55.26.

Twist Bioscience (NASDAQ:TWST) last announced its earnings results on Thursday, May 2nd. The company reported ($0.79) earnings per share for the quarter, beating the consensus estimate of ($0.84) by $0.05. The company had revenue of $75.30 million for the quarter, compared to the consensus estimate of $70.70 million. Twist Bioscience had a negative return on equity of 31.61% and a negative net margin of 69.24%. The company’s revenue was up 25.1% on a year-over-year basis. During the same period last year, the business posted ($1.06) EPS. On average, research analysts predict that Twist Bioscience Co. will post -3.08 earnings per share for the current year.

Analysts Set New Price Targets

Several equities research analysts have recently weighed in on TWST shares. Scotiabank raised their target price on Twist Bioscience from $43.00 to $48.00 and gave the stock a “sector outperform” rating in a research report on Monday, May 6th. Robert W. Baird raised their price target on Twist Bioscience from $39.00 to $40.00 and gave the stock an “outperform” rating in a research note on Friday, May 3rd. Guggenheim assumed coverage on Twist Bioscience in a research note on Tuesday, June 4th. They set a “buy” rating and a $53.00 price target on the stock. Evercore ISI raised their price target on Twist Bioscience from $46.00 to $50.00 and gave the stock an “outperform” rating in a research note on Friday, May 3rd. Finally, Barclays raised their price target on Twist Bioscience from $40.00 to $45.00 and gave the stock an “overweight” rating in a research note on Friday, May 3rd. Eight investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, Twist Bioscience presently has an average rating of “Buy” and a consensus target price of $46.63.

Institutional Trading of Twist Bioscience

Several hedge funds have recently modified their holdings of TWST. Federated Hermes Inc. acquired a new stake in shares of Twist Bioscience in the 3rd quarter valued at approximately $29,000. EdgeRock Capital LLC acquired a new stake in shares of Twist Bioscience in the 4th quarter valued at approximately $30,000. Headlands Technologies LLC acquired a new stake in shares of Twist Bioscience in the 1st quarter valued at approximately $124,000. International Assets Investment Management LLC lifted its holdings in shares of Twist Bioscience by 3,519.8% in the 4th quarter. International Assets Investment Management LLC now owns 4,018 shares of the company’s stock valued at $148,000 after buying an additional 3,907 shares during the period. Finally, Brown Advisory Inc. acquired a new stake in shares of Twist Bioscience in the 4th quarter valued at approximately $225,000.

Twist Bioscience Company Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.